2009 News Releases
CSL Behring Awards Fourth Round of LEAD Grants
CSL Behring, has awarded four advocacy grants totaling $87,000 to patient organizations in the United States through the Local Empowerment for Advocacy Development (LEAD) program. LEAD grants support grassroots advocacy efforts by organizations committed to helping people who use plasma-derived or recombinant therapies manage their health conditions.
Patient and Healthcare Provider Convenience Focus of Packaging Enhancements for Humate-P from CSL Behring
Junior Athletes Honored by CSL Behring at National Hemophilia Foundation's Annual Meeting
CSL Behring announced today the national winners of the 8th annual Gettin' in the GameSM Junior National Championship (JNC). Developed by CSL Behring, provider of the hemophilia treatment Helixate FS (Antihemophilic Factor, Recombinant), the JNC is a series of one-day events held throughout the country that provide hundreds of children with bleeding disorders the opportunity to participate in a golf and baseball competition.
CSL Behring Announces FDA Approval of Berinert®, First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Hereditary Angioedema in U.S.
CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Berinert C1-Esterase Inhibitor, Human for the treatment of acute abdominal or facial attacks of hereditary angioedema (HAE), a rare and serious genetic disorder, in adult and adolescent patients.
CSL Behring Solicits Proposals for LEAD Grants to Support Patient Advocacy Efforts
CSL Behring, a global leader in the plasma-protein biotherapeutics industry, is calling for grant requests through its Local Empowerment for Advocacy Development (LEAD) program. The LEAD program awards funds to United States patient organizations that assist people with rare diseases in advocating for continued access to health care and life-saving plasma protein therapies.
Helixate FS from CSL Behring Now Available in 3000 IU Dosage Strength to Improve Patient Convenience
Hemophilia A patients who require high doses of Helixate® FS, Antihemophilic Factor (Recombinant), can now benefit from greater convenience in administering their treatment, thanks to a new 3000 IU (international unit) dosage strength. CSL Behring announced today that this new dosage strength is available in the U.S., allowing many patients to reduce reconstitution time by eliminating the need to mix and pool multiple vials of Helixate FS.